These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 31085078)

  • 1. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
    Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
    Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
    Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
    ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
    Lee TJ; Yoo JY; Shu D; Li H; Zhang J; Yu JG; Jaime-Ramirez AC; Acunzo M; Romano G; Cui R; Sun HL; Luo Z; Old M; Kaur B; Guo P; Croce CM
    Mol Ther; 2017 Jul; 25(7):1544-1555. PubMed ID: 28109960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
    Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
    BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity.
    Jin YY; Andrade J; Wickstrom E
    PLoS One; 2015; 10(12):e0142574. PubMed ID: 26629823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-κB signaling and reducing NLRP3 expression in triple-negative breast cancer.
    Zheng W; Peng W; Qian F; Zhang M; Duan B; Fan Z; Xie Y; Fu X
    Cancer Chemother Pharmacol; 2024 Jul; 94(1):67-78. PubMed ID: 38456956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
    Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
    Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles.
    Zhang T; Wu Y; Yang D; Wu C; Li H
    Biochem Biophys Res Commun; 2021 Jun; 558():107-113. PubMed ID: 33906109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor targeting and therapeutic assessments of RNA nanoparticles carrying α9-nAChR aptamer and anti-miR-21 in triple-negative breast cancers.
    Liao YC; Cheng TC; Tu SH; Chang J; Guo P; Chen LC; Ho YS
    Mol Ther Nucleic Acids; 2023 Sep; 33():351-366. PubMed ID: 37547295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMP3 promotes TNBC stem cell property through miRNA-34a regulation.
    Huang QD; Zheng SR; Cai YJ; Chen DL; Shen YY; Lin CQ; Hu XQ; Wang XH; Shi H; Guo GL
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2688-2696. PubMed ID: 29771420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 19. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.